HQ Team
June 17, 2026: The US Food and Drug Administration has approved Utebzi (tebipenem pivoxil), an antibiotic pill for people suffering from complicated urinary tract infections (cUTIs), a more severe form of UTI. The drug, developed jointly by GSK and Spero Therapeutics, was approved Tuesday.
cUTIs carry the risk of kidney infections, including pyelonephritis (a kidney infection that happens when bacteria travel up from the bladder), caused by specific drug-resistant bacteria, and higher complications with few or no other oral treatment options. It’s for the first time that this class of antibiotics(Carbapenemsare) is coming in pill form rather than only through an IV drip in hospital.
Pill matters
Carbapenemsare is considered a backstop antibiotic class that doctors turn to when more common antibiotics have stopped working. Until now, carbapenems were only available as an intravenous infusion, which usually means a hospital stay or repeated clinical visits.
More than 3 million cases of cUTI are treated in the US every year, and treatment failure affects as many as a third of patients, according to GSK, citing peer-reviewed cohort data. UTI burden trends from 1990 to 2021, according to a research, found that the number of UTI cases increased by 66.45%, reaching 4.49 billion cases, with an ASIR of 5,531.88 per 100,000 population. The greatest incidence of UTIs was seen in women and older adult men. A Nephrology Dialysis Transplantation study estimated that drug-resistant UTIs were linked to roughly 260,000 deaths worldwide in 2019 alone, underscoring how serious the resistance problem driving this approval really is.
“With antibiotic resistance continuing to rise, patients and healthcare professionals need new treatment options,” said Tony Wood, GSK’s chief scientific officer. The approval, he said, gives doctors an oral alternative that “could help reduce reliance on hospital-based intravenous care.”
Clinical trial findings
The approval rests on results from the PIVOT-PO phase 3 trial (a late-stage human trial designed to confirm a drug works and is safe before approval), which tested the new pill against the standard IV carbapenem, imipenem-cilastatin, in 1,690 hospitalised patients with cUTI or pyelonephritis.
The trial was designed to show “non-inferiority,” meaning researchers wanted to prove the pill worked about as well as the IV version, not necessarily better. It did: 58.5 per cent of patients on the oral drug recovered, measured as a combination of symptom relief and lab-confirmed clearance of the infection, compared with 60.2 per cent on the IV drug, a difference small enough to meet the trial’s pre-set bar for similarity.
Dr Bilal Chughtai, chief of urology at Plainview Hospital, Northwell Health, called the approval “a major milestone,” noting that the current standard of IV-only treatment “places a serious burden” on patients and hospitals alike. An oral option, he said, could let more people be treated outside the hospital altogether.
The most commonly reported side effects in the trial were diarrhoea and headache, both described as mild to moderate. The FDA’s own review also listed nausea, abdominal pain, raised liver enzymes, and C. difficile infection (a bacterial gut infection that can sometimes follow antibiotic use) among possible side effects. People with a known allergy to carbapenems or other beta-lactam antibiotics, or with certain rare metabolic conditions affecting carnitine levels, are advised to avoid the drug.
Drug availability
Utebzi is expected to reach US patients by the end of 2026, GSK said. The drug received Priority Review, Fast Track, and Qualified Infectious Disease Product designations from the FDA, regulatory fast-lanes reserved for treatments addressing serious unmet medical needs.
The drug’s development was partly funded by the US government’s Biomedical Advanced Research and Development Authority (BARDA), an agency that backs medical countermeasures against public health threats including antimicrobial resistance.
